Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts

A. S. Galyavich,I. V. Fomin,I. R. Gaisin,F. V. Valeeva,N. G. Vinogradova,A. S. Salasyuk,E. I. Tarlovskaya,N. R. Khasanov,A. M. Shutov,E. N. Volodina,L. V. Grekhova,P. S. Guseva,D. V. Duplyakov, O. V. Zanozina, Yu. V. Zolotova,S. V. Kanysheva,Z. F. Kim, S. K. Kononov,V. P. Kuzmin, S. S. Markiyanova,M. V. Menzorov,S. A. Pomosov,A. P. Rebrov,S. N. Tolstov

Russian Journal of Cardiology（2021）

Cited 1|Views3

No score

Abstract

At an online meeting of experts held on May 14, 2021 additional research results on a sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with reduced ejection fraction were considered. According to the data from the EMPEROR-Reduced international study, cardiovascular and renal effects of empagliflozin therapy in patients with and without type 2 diabetes (T2D) were analyzed. A number of proposals and recommendations was accepted regarding the further study of cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with heart failure, regardless of the T2D presence.

Translated text

Key words

empagliflozin,heart failure,cardiovascular mortality,chronic kidney disease,emperor-reduced study

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined